DOCSLIB.ORG

Clinical Significance of Nm23-H1 Proteins Expressed on Cell Surface

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Significance of Nm23-H1 Proteins Expressed on Cell Surface Leukemia (2003) 17, 196–202 2003 Nature Publishing Group All rights reserved 0887-6924/03 $25.00 www.nature.com/leu Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin’s lymphoma N Niitsu1, Y Honma2, K Iijima3, T Takagi4, M Higashihara1, U Sawada5 and J Okabe-Kado2 1Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan; 2Saitama Cancer Center Research Institute, Saitama, Japan; 3First Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan; 4Hematology- Oncology Division, Chiba, Cancer Center Hospital, Chiba, Japan; and 5First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan The nm23 gene was isolated as a metastasis suppressor gene in both aggressive NHL and AML.7–9 In a collaborative study that exhibits low expression in high-level metastatic cancer between many institutions involving a large number of cells. Its gene is related to the prognosis of acute myelogenous leukemia (AML) and non-Hodgkin’s lymphoma (NHL). In this patients, we found that serum nm23-H1 was an important study, we examined the expression of nm23-H1 protein on the independent prognostic factor in NHL for diffuse large B cell lymphoma cell surface of NHL. In 28 of 108 cases (25.9%), we lymphoma (DLBCL) and peripheral T cell lymphoma (PTCL).8 observed Ն20% of cell surface nm23-H1 protein expression We also examined four distinct risk groups defined by the and expression was especially high in peripheral T cell lym- widely used clinical international prognostic index (IPI) and phomas and extranodal NK/T cell lymphomas. We also demonstrated that when serum nm23-H1 protein levels are observed a significant correlation between serum nm23-H1 level and cell surface nm23-H1 expression levels. In patients high, prognosis is poor in all four risk groups. Given these with high levels of cell surface nm23-H1 expression, overall and results, measurement of nm23-H1 protein may be useful in progression-free survival rates were significantly lower than the treatment method selection process. Whether such serum those in patients with low surface nm23-H1 expression levels. nm23-H1 protein is directly produced by lymphoma cells is When surface nm23-H1 and serum nm23-H1 were combined, unclear, but its production appears to reflect the prognosis of patients with high levels of both exhibited a poorer prognosis lymphoma. In this study, to examine the clinical significance than patients with a high level of one or the other. These results indicate that in addition to serum nm23-H1, cell surface nm23- of nm23-H1 protein on the surface of lymphoma cells, we H1 may be used as a prognostic factor in planning a treatment studied the relationships of surface nm23-H1 to serum nm23- strategy. The nm23-H1 protein appears to be intimately related H1 and other cell surface markers by flow cytometry measure- to biological aggressiveness of lymphoma and, therefore, ment and tracked the subsequent survival rates. might be a molecular target of NHL treatment. Leukemia (2003) 17, 196–202. doi:10.1038/sj.leu.2402699 Keywords: nm23-H1 proteins; cell surface; non-Hodgkin’s lym- phoma; prognostic factor Materials and methods Patients Introduction We measured cell surface nm23-H1 expression from February 1999 to March 2000 in a consecutive series of 108 patients The first nm23 gene was isolated on the basis of its reduced with untreated NHL (62 men and 46 women; median age, 68 expression in highly metastatic murine melanoma cell lines, years; age range, 22–78 years) whose clinical course was as compared with their nonmetastatic counterparts, and has being managed by the lymphoma treatment study group in therefore been proposed as a metastatic suppressor gene.1 Japan. The cases were classified morphologically according Subsequently, high homology between nm23 proteins and to the REAL schema10 as defined elsewhere with or without nucleoside diphosphate kinases (NDPK) has been identified in adjunctive immunohistochemical and molecular studies. Of a number of species.2 We found that a differentiation inhibi- these 108 patients with NHL, 79 presented with B cell neo- tory factor purified from conditioned medium of a differen- plasms and 29 with T cell neoplasms. Of the 79 patients with tiation-resistant mouse myeloid leukemia cell line was ident- B cell neoplasms, three had B cell chronic lymphocytic leuke- ical to the nm23 protein.3,4 In humans, eight nm23 isotypes mia (CLL), three had mucosa-associated lymphoid tissue (nm23-H1, nm23-H2, DR-nm23, nm23-H4, nm23-H5, nm23- (MALT), five had mantle cell lymphoma (MCL), 13 had follicu- H6, nm23-H7 and nm23-H8) have been identified to date.5 lar lymphoma (FL), and 55 had DLBCL. Of the 29 patients Immunohistochemical studies have reported that patients with with T cell neoplasms, 18 had PTCL, two had anaplastic large high-grade non-Hodgkin’s lymphoma (NHL) and Hodgkin’s cell lymphoma (ALCL), six had extranodal NK/T cell lym- lymphoma exhibit significantly higher levels of nm23-H1 phoma (NK/T), and three had adult T cell leukemia/lymphoma expression than do those with low-grade NHL.6 (ATLL). Clinical staging was performed according to the Ann Recently, we established an enzyme-linked immunosorbent Arbor classification system.11 Evaluation included a complete assay (ELISA) technique to determine the serum level of nm23- history and physical examination, chest roentgenography, H1 protein. We previously reported that serum levels of bone marrow aspiration and biopsy, computed tomography nm23-H1 in aggressive NHL and acute myelogenous leuke- of the chest, abdomen and pelvis, hemogram and differential mia (AML) were significantly higher than those in controls, counts and routine biochemistry tests. Laparotomy was not and that high nm23-H1 levels correlated with poor prognosis performed for staging. The IPI was determined in all NHL cases.12 Patients with aggressive NHL and disseminated dis- ease were treated with cyclophosphamide, vincristine, predni- Correspondence: N Niitsu, Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1-15-1 Kitasato, solone, bleomycin, doxorubicin and procarbazine (COP- 13 Sagamihara-shi, Kanagawa 228-8555, Japan; Fax: +81-42-778-9978 BLAM), cyclophosphamide, doxorubicin, vincristine and Received 4 February 2002; accepted 19 June 2002 prednisolone (CHOP),14 or another anthracycline-containing Cell surface nm23-H1 and NHL N Niitsu et al 197 combination chemotherapy regimen. Indolent lymphoma was strate and an alkaline phosphatase-detecting kit (BioRad Lab). in most cases treated with a single agent or cyclophospham- The reaction was stopped with 50 ␮l of 0.4 N NaOH. ide, vincristine and prednisone (COP). Patients were re-evalu- Absorbance was measured at 405–415 nm with a correction ated every few months, undergoing physical examination, wavelength of 620–630 nm using a microplate reader. hemogram and differential counts, biochemistry tests, and computed tomography of the chest, abdomen and pelvis. The median follow-up time was 21 months (range, 15–25 months), Statistical analysis and the final follow-up examination was carried out in April 2001. Approval of the study protocol was obtained from the The patients’ characteristics were compared using chi-square institutional review board at each participating institute. Infor- tests. Judgment criteria used for the analysis were progression- med consent was obtained from patients according to the free survival (PFS) and overall survival (OS). Progression was Declaration of Helsinki. defined as a progression of the lymphoma in nonresponding patients or partial response patients, a relapse for complete response patients, or death from any cause without pro- Flow cytometry for human cell surface nm23-H1 gression. PFS was calculated as the time from randomization to the first progression. Patients who did not experience a pro- The compound 7-amino-actinomycin D (7AAD) was pur- gression at the time of analysis were censored at the most chased from Sigma Chemical (St Louis, MO, USA). The drug recent date of disease assessment or at the stop date if the was diluted in phosphate-buffered saline (PBS) as a 25 ␮g/ml ° most recent date was later. OS was measured from the date stock solution, which was stored at 4 C. FITC-conjugated of randomization to the date of death, regardless of cause. monoclonal anti-nm23-H1 antibody was purchased from Sei- Patients who were still living at the time of analysis were cen- kagaku Kougyo (Tokyo, Japan). PE-conjugated anti-Leu4 sored at the most recent date of disease assessment or at the (CD3), Leu3a (CD4), Leu2a (CD8), LeuM5 (CD11c), Leu11a stop date if the most recent date was later. Survival analysis (CD16), and Leu12 (CD19) were purchased from Becton was performed according to the Kaplan–Meier method.15 The Dickinson (Cowley, UK) and CD5, CD10 and CD56 were pur- statistical significance of differences in survival was determ- chased from BD PharMingen (San Diego, CA, USA). FITC- and ined by the log-rank and generalized Wilcoxon’s tests.16 Dif- PE-conjugated murine IgG monoclonal antibodies of unre- ferences between groups were evaluated by the Mann–Whit- lated specificities were always used as controls. ney U test (nonparametric analysis),17 and P < 0.05 was taken Fresh tissues were transported immediately in RPMI 1640 to indicate significance. solution to the flow cytometry laboratory. Lymphocytes were disaggregated and released from solid tissue by injection of RPMI 1640 solution. Up to 1 × 106 cells were pelleted, incu- bated with 5 ␮l of 7AAD solution (final 1 ␮g/ml), 50 ␮lof Results FITC-conjugated monoclonal antibody, and PE-conjugated monoclonal antibody for 30 min at 4°C while protected from Correlation between nm23-H1 expression and serum light, and then pelleted by centrifugation. The supernatant was parameters or cell surface markers removed, and the cells were resuspended in Cell FIX solution (Becton Dickinson).
Load more

Recommended publications
  • To the New City of Brockville Zoning By-Law
    BROCKVILLE FREQUENTLY ASKED QUESTIONS | SUMMARY OF CHANGES | HOW TO USE THE NEW ZONING BY-LAW GUIDE TO THE NEW CITY OF BROCKVILLE ZONING BY-LAW FEBRUARY 2014 TABLE OF CONTENTS FREQUENTLY ASKED What is a Zoning By-law? . 2 QUESTIONS Why is the City updating its Zoning By-law? . 2 What is the City of Brockville’s Official Plan? . 2 What does the City’s Official Plan say about the P .2 Zoning By-law? . 2 How does the City enforce and implement its Zoning By-law? 3 How will the Zoning By-law update affect me? . 4 HOW HAS THE What if my zoning did change? Will the buildings and the use of my property continue to be legal? . 4 ZONING BY-LAW Have you recently applied for or received approval for a CHANGED? planning application or building permit? . 4 Modernized, expanded definitions . 7 P .5 Improved format and organization . 8 Special provisions and design requirements for the Downtown and Central Waterfront Area – New Schedule “B” . 9 HOW DO I New zones for future neighbourhoods . 10 USE THE NEW Other changes to the Zoning Map (Schedule “A”) . 11 ZONING BY-LAW? Structure of the Zoning By-law . 12 How to check your zoning and identify P .12 Applicable Regulations . 13 HOW DO I How do I provide input on the Draft Zoning By-law? . 18 PROVIDE INPUT ON THE DRAFT ZONING BY-LAW P .18 FREQUENTLY ASKED QUESTIONS WHY IS THE CITY UPDATING ITS ZONING BY-LAW? The City is updating its Zoning By-law because the City’s new Official Plan has been WHAT IS A ZONING approved and is now in-effect .
    [Show full text]
  • ELIGIBILITY Para-Cycling Athletes: Must Be a United States Citizen With
    ELIGIBILITY Para-cycling Athletes: Must be a United States citizen with a USA racing nationality. LICENSING National Championships: Riders may have a current International or Domestic USA Cycling license (USA citizenship) or Foreign Federation license showing a USA racing nationality to register. World Championships Selection: Riders must have a current International USA Cycling license with a USA racing nationality on or before June 20, 2019 in order to be selected for the Team USA roster for the 2019 UCI Para-cycling Road World Championships. Selection procedures for the World Championships can be found on the U.S. Paralympics Cycling Website: https://www.teamusa.org/US- Paralympics/Sports/Cycling/Selection-Procedures REGULATIONS General: All events conducted under UCI Regulations, including UCI equipment regulations. Road Race and Time Trials: • No National Team Kit or National championship uniforms are allowed. • For the Road Race, only neutral service and official’s cars are allowed in the caravan. • For the Time Trial, bicycles and handcycles must be checked 15 minutes before the athlete’s assigned start time. Courtesy checks will be available from 1 hour before the first start. No follow vehicles are allowed. • For all sport classes in the road race, athletes are required to wear a helmet in the correct sport class color, or use an appropriately color helmet cover, as follows: RED MC5, WC5, MT2, MH4, WH4, MB WHITE MC4, WC4, MH3, WH3, WB, WT2 BLUE MC3, WC3, MH2, WT1 BLACK MH5, WH5, MC2, WC2, MT1 YELLOW MC1, WC1, WH2 GREEN MH1 ORANGE WH1 Handcycle Team Relay (TR): New National Championship event run under UCI and special regulations below: • Team Requirements: Teams eligible for the National Championship Team Relay, must be respect the following composition: o Teams of three athletes o Using the table below, the total of points for the three TR athletes may not be more than six (6) points which must include an athlete with a scoring point value of 1.
    [Show full text]
  • Mn. Rita Thistle ~Ested\
    ·- .. • • • +. RDAY . MAU II 14, 1931 Mn. Rita Thistle ~ested\ ._ . · BECK&T SENTENCED f /\IALITY AT DRY DOCK Charged Wit)l MurWof.. H~~d Prom th yd11 y R ord Thomae Peddle Killed The Incemore arri ed in ~1·n the f II win * n • 01111t REGINALD BOLAND HELD AS MATERIAL WITNESS t. John' from Liverpool on tl11' pr 11e ding · wh l'J I Rock,r tL :.vn, nu \\'rein'. dnv nl'tl'rnoon nbont Thursday, an<f\-sails for IUlifax • n t r1H•Nl. ;t:Ul. Thomn. l'1•tldl1'. ngt•tl !l_. and Bo ton tOday J turday) and aturday aftern0t1n nt n qu r- 1 Rr k. 011 \\' •dn .-clay. ;\fnr h 4th. l i'1·kl'I t .. wh ll · wu · hrou~h fo r 1•1111H1 of du ·k lnhor •r , wu ii; due in this port on Thntsday, ter past fi\'e o'clock, Hi ta Thi ti .-.t 10 A. ~r. thr cuttrt W1 al'iui.r 11 bin• ov•r• n kill1•<l in~ 1 1111 tly wh1•11 h1• f •II from 1 • l\lar h 19. he is heduled to widow of John T hi tic, wn nr· • Two mi1111tl'. aft<> r ".\!rs. 'I histlc o\'l' r hil'> f11dNI •my snit. to k I i1 t ht• p 1r111w1 of t ht• <I ·k. , triki111: sail Crom B08ton on turday, r ted on n char of murcl 'ring l111tl h 'Cll nl'rnig111•1 1. l ~ : i::innld I ~ \'1•r.lict 1·11lml y. niukiui: nu' c Ill· I h1• ti r~f g11 ll1•ry 11 111 I rol ni: from - 1\f nrch 21, and ha accommodation her It t band on D c<>mU~' r :n.
    [Show full text]
  • Para Cycling Information Sheet About the Sport Classification Explained
    Para cycling information sheet About the sport Para cycling is cycling for people with impairments resulting from a health condition (disability). Para athletes with physical impairments either compete on handcycles, tricycles or bicycles, while those with a visual impairment compete on tandems with a sighted ‘pilot’. Para cycling is divided into track and road events, with seven events in total. Classification explained In Para sport classification provides the structure for fair and equitable competition to ensure that winning is determined by skill, fitness, power, endurance, tactical ability and mental focus – the same factors that account for success in sport for able-bodied athletes. The Para sport classification assessment process identifies the eligibility of each Para athlete’s impairment, and groups them into a sport class according to the degree of activity limitation resulting from their impairment. Classification is sport-specific as an eligible impairment affects a Para athlete’s ability to perform in different sports to a different extent. Each Para sport has a different classification system. Standard Classification in detail Para-Cycling sport classes include: Handcycle sport classes H1 – 5: There are five different sport classes for handcycle racing. The lower numbers indicate a more severe activity limitation. Para athletes competing in the H1 classes have a complete loss of trunk and leg function and limited arm function, e.g. as a result of a spinal cord injury. Para athletes in the H4 class have limited or no leg function, but good trunk and arm function. Para cyclists in sport classes H1 – 4 compete in a reclined position. Para cyclists in the H5 sport class sit on their knees because they are able to use their arms and trunk to accelerate the handcycle.
    [Show full text]
  • (VA) Veteran Monthly Assistance Allowance for Disabled Veterans
    Revised May 23, 2019 U.S. Department of Veterans Affairs (VA) Veteran Monthly Assistance Allowance for Disabled Veterans Training in Paralympic and Olympic Sports Program (VMAA) In partnership with the United States Olympic Committee and other Olympic and Paralympic entities within the United States, VA supports eligible service and non-service-connected military Veterans in their efforts to represent the USA at the Paralympic Games, Olympic Games and other international sport competitions. The VA Office of National Veterans Sports Programs & Special Events provides a monthly assistance allowance for disabled Veterans training in Paralympic sports, as well as certain disabled Veterans selected for or competing with the national Olympic Team, as authorized by 38 U.S.C. 322(d) and Section 703 of the Veterans’ Benefits Improvement Act of 2008. Through the program, VA will pay a monthly allowance to a Veteran with either a service-connected or non-service-connected disability if the Veteran meets the minimum military standards or higher (i.e. Emerging Athlete or National Team) in his or her respective Paralympic sport at a recognized competition. In addition to making the VMAA standard, an athlete must also be nationally or internationally classified by his or her respective Paralympic sport federation as eligible for Paralympic competition. VA will also pay a monthly allowance to a Veteran with a service-connected disability rated 30 percent or greater by VA who is selected for a national Olympic Team for any month in which the Veteran is competing in any event sanctioned by the National Governing Bodies of the Olympic Sport in the United State, in accordance with P.L.
    [Show full text]
  • Should the Para-Cycling Classification System Be Reclassified?
    Should the para-cycling classification system be reclassified? David Borg1, John Osborne2, Johanna Liljedahl3, Michele Foster1, Carla Nooijen3 1The Hopkins Centre, Menzies Health Institute Queensland, Griffith University, Brisbane, Australia. 2School of Exercise and Nutrition Sciences, Queensland University of Technology, Brisbane, Australia. 3The Swedish School of Sport and Health Sciences (GIH), Stockholm, Sweden. Introduction Results Para-cycling athletes compete on bicycles (C1–5), handcycles The number of men in C1, C2, C3, C4 and C5 was 32, 76, 63, (H1–5) and tricycles (T1-2) in classes based on their functional 76, and 87, respectively. Nineteen men competed in T1 and 58 disability. Higher classes reflect less functional impairment. Para- in T2. The age range of men was 14–62 years. cycling classification is governed by the Union Cycliste Inter- The number of women competing in C1, C2, C3, C4 and C5 was nationale (UCI). The system aims to promote participation in the 4, 18, 16, 20 and 28, respectively. Eleven competed in T1 and sport, by controlling for the impact of impairment on the outcome 15 in T2. Women’s age ranged 17–55 years. of competition. Road race velocity for the bicycling and tricycling is shown in Recently, the separation between adjacent handcycling classes for Figure 1. Comparisons between adjacent classes for men and official UCI events was described––providing benchmarks for women are displayed in Table 2. active and potential athletes. Unfortunately, similar evaluation of the bicycling and tricycling disciplines has not been considered. With the expectation of C4 and C5 for women, the analysis showed that men's and women's road race performance was This study aimed to described the separation between adjacent statistically different between adjacent classes for bicycling and classes, based on performance, in UCI road race events for tricycling.
    [Show full text]
  • The Paralympic Athlete Dedicated to the Memory of Trevor Williams Who Inspired the Editors in 1997 to Write This Book
    This page intentionally left blank Handbook of Sports Medicine and Science The Paralympic Athlete Dedicated to the memory of Trevor Williams who inspired the editors in 1997 to write this book. Handbook of Sports Medicine and Science The Paralympic Athlete AN IOC MEDICAL COMMISSION PUBLICATION EDITED BY Yves C. Vanlandewijck PhD, PT Full professor at the Katholieke Universiteit Leuven Faculty of Kinesiology and Rehabilitation Sciences Department of Rehabilitation Sciences Leuven, Belgium Walter R. Thompson PhD Regents Professor Kinesiology and Health (College of Education) Nutrition (College of Health and Human Sciences) Georgia State University Atlanta, GA USA This edition fi rst published 2011 © 2011 International Olympic Committee Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientifi c, Technical and Medical business to form Wiley-Blackwell. Registered offi ce: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offi ces, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identifi ed as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • SPECTATOR GUIDE U.S. Paralympics Cycling Open Cummings Research Park, Huntsville, Alabama April 17-18, 2021 Come Cheer for Our P
    SPECTATOR GUIDE U.S. Paralympics Cycling Open Cummings Research Park, Huntsville, Alabama April 17-18, 2021 Come Cheer for our Paralympic Cyclists! The Huntsville/Madison County community is excited to host U.S. Paralympics Cycling on Saturday and Sunday, April 17-18, 2021 in Cummings Research Park. The U.S. Paralympics Cycling Open presented by Toyota, is one of four domestic cycling events and the second opportunity for Para-cyclists to qualify for the Summer Paralympics in Tokyo this summer. This is also the return to competitive racing for these outstanding athletes who have not competed in over a year due to the ongoing COVID-19 pandemic. In fact, this event has taken on more importance in the qualifying circuit as other international qualifying events have been cancelled due to the pandemic. We expect approximately 100 Para athletes to visit Huntsville. The athletes will compete in three different types of road cycling events including the men’s and women’s road race, individual time trial, and handcycling team relay. Learn more about U.S. Paralympics Cycling here: USParaCycling.org This guide serves as an FAQ. It provides information on how and where you can watch the action during race weekend. Link to: Parking Viewing Restrooms What’s on the Schedule Each Day Show Your Support! Athletes to Watch Page 1 Do I need tickets? No! The public is invited, and this is a free event. The events will happen rain or shine. Bring the family, pack a cooler, bring chairs and a blanket, and come watch along the outside ring of Explorer Boulevard, the loop of Cummings Research Park West.
    [Show full text]
  • Letters to Assessors 2006-010
    STATE OF CALIFORNIA BETTY T. YEE STATE BOARD OF EQUALIZATION Acting Member PROPERTY AND SPECIAL TAXES DEPARTMENT First District, San Francisco 450 N STREET, SACRAMENTO, CALIFORNIA PO BOX 942879, SACRAMENTO, CALIFORNIA 94279-0064 BILL LEONARD Second District, Sacramento/Ontario 916 445-4982 FAX 916 323-8765 www.boe.ca.gov CLAUDE PARRISH Third District, Long Beach February 6, 2006 JOHN CHIANG Fourth District, Los Angeles STEVE WESTLY State Controller, Sacramento RAMON J. HIRSIG Executive Director No. 2006/010 CORRECTION TO COUNTY ASSESSORS: REVENUE AND TAXATION CODE SECTION 69.5: PROPOSITIONS 60, 90, AND 110 Section 69.5 was added to the Revenue and Taxation Code1 in 1987 to implement Proposition 60, which amended section 2 of article XIII A of the California Constitution to authorize the Legislature to provide for the transfer of a base year value from a principal residence2 to a replacement dwelling within the same county by a homeowner age 55 and over. Subsequently, section 69.5 was amended to implement Proposition 90, which authorized county boards of supervisors to adopt ordinances allowing base year value transfers between different counties, and Proposition 110, which extended these provisions to severely and permanently disabled persons of any age. After summarizing the key elements of section 69.5, this letter provides answers to frequently asked questions about its application. This letter supersedes Letters To Assessors No. 87/71 (dated September 11, 1987) and No. 88/10 (dated February 11, 1988). SUMMARY OF SECTION 69.5 Section 69.5 allows a homeowner to transfer the existing base year value to a replacement dwelling provided that: • If the replacement property is located in a different county than the original property, then the county in which the replacement dwelling is located must have a current ordinance allowing base year value transfers from other counties.
    [Show full text]
  • Bacterial Lipoteichoic Acid Attenuates Toll-Like Receptor Dependent Dendritic Cells Activation and Inflammatory Response
    pathogens Article Bacterial Lipoteichoic Acid Attenuates Toll-Like Receptor Dependent Dendritic Cells Activation and Inflammatory Response 1,2,3, , 4,5, 3, 2,6 7,8 Suguru Saito * y, Alato Okuno y, Duo-Yao Cao y, Zhenzi Peng , Hui-Ya Wu and Shu-Hui Lin 8 1 Bio-fluid Biomarker Center, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 9502181, Japan 2 Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; [email protected] 3 College of Animal Science and Technology, Northwest A&F University, Shaanxi 712100, China; [email protected] 4 Department of Health and Nutrition, Tsukuba international university, Ibaraki 3000051, Japan; [email protected] 5 Department of Food and Life Sciences. College of Agriculture, Ibaraki University, Ibaraki 3000393, Japan 6 Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha 410008, China 7 College of Health Science, Trans World University, Douliu 64063, Taiwan; [email protected] 8 Medical Science International, Taipei 115, Taiwan; [email protected] * Correspondence: [email protected]; Tel.: +1-706-399-9356 These authors contributed equally to this work. y Received: 9 September 2020; Accepted: 6 October 2020; Published: 8 October 2020 Abstract: Toll-like receptor (TLR) signaling is an indispensable factor in immune cells activation. Many TLR ligands have been identified, and were characterized the immunological functions such as inflammatory cytokine production in immune cells. However, the anti-inflammatory response in TLR ligand-mediated manner is poorly understood. In this report, we show that bacterial lipoteichoic acid (LTA), which is a TLR2 ligand from gram-positive bacteria including Staphylococcus aureus (S.
    [Show full text]
  • Amendments to Regulations with Effect on 01.02.2019
    AMENDMENTS TO REGULATIONS WITH EFFECT ON 01.02.2019 Factored events 16.1.005 In case of factored event (gender and/or sport class), standard performance factors in the table below must be applied to ensure equity between the combined sport classes. Table of standard performance factors for road events Division C C5 Men 100.00 C4 Men 97.63%% 100.00 C3 Men 93.19% 95.45%% 100.00 C2 Men 89.60% 91.78% 96.15%% 100.00 C5 Women 87.73% 89.86% 94.14% 97.91%% 100.00 C4 Women 85.65% 87.73% 91.91% 95.59% 97.63%% 100.00 C1 Men 86.15% 88.24% 92.45% 96.15% 98.20% 100.58% 100.00 C3 Women 81.76% 83.74% 87.73% 91.25% 93.19% 95.45%% 94.90%% 100.00 C2 Women 78.61% 80.51% 84.35% 87.73% 89.60% 91.78% 91.24% 96.15%% 100.00 C1 Women 75.58% 77.41% 81.10% 84.35% 86.15% 88.24% 87.73% 92.45% 96.15%% 100.00 % Division H H5 Men 100.00 H4 Men 100.00% 100.00 H3 Men 97.23%% 97.23%% 100.00 H5 Women 87.73% 87.73% 90.23%% 100.00 H4 Women 87.73% 87.73% 90.23% 100.00% 100.00 H3 Women 85.30% 85.30% 87.73% 97.23%% 97.23%% 100.00 H2 Men 82.71% 82.71% 85.07% 94.28% 94.28% 96.96%% 100.00 H2 Women 72.56% 72.56% 74.63% 82.71% 82.71% 85.07% 87.73%% 100.00 H1 Men 58.79% 58.79% 60.46% 67.01% 67.01% 68.92% 71.08% 81.02%% 100.00 H1 Women 51.58% 51.58% 53.05% 58.79% 58.79% 60.46% 62.36% 71.08% 87.73%% 100.00 % Division T T2 Men 100.00 T2 Women 87.73%% 100.00 T1 Men 82.35% 93.87%% 100.00 T1 Women 72.25% 82.35% 87.73%% 100.00 % Division B B Men 100.00 B Women 87.73%% 100.00 % Union Cycliste Internationale Page 1 / 6 1er février 2019 Table of standard performance factors for track events
    [Show full text]
  • R-Spondin2 Promotes Hematopoietic Differentiation of Human Pluripotent Stem Cells by Activating TGF Beta Signaling
    Wang et al. Stem Cell Research & Therapy (2019) 10:136 https://doi.org/10.1186/s13287-019-1242-9 RESEARCH Open Access R-spondin2 promotes hematopoietic differentiation of human pluripotent stem cells by activating TGF beta signaling Yv Wang1,2, Jie Gao1,2, Hongtao Wang1,2, Mengge Wang1,2, Yuqi Wen1,2, Jiaojiao Guo3, Pei Su1,2, Lihong Shi1,2, Wen Zhou3* and Jiaxi Zhou1,2* Abstract Background: Human pluripotent stem cells (hPSCs) provide supplies of potential functional blood cells to suffice the clinical needs. However, the underlying mechanism of generating genuine hematopoietic stem cells (HSCs) and functional blood cells from hPSCs remains largely elusive. Method: In this study, we supplied R-spondin2 exogenously during hematopoietic differentiation of hPSCs under various culture conditions and analyzed the production of hematopoietic progenitor cells (HPCs). We further added R-spondin2 at different temporal window to pin down the stage at which R-spondin2 conferred its effects. RNA- SEQ-based gene profiling was applied to analyze genes with significantly altered expression and altered signaling pathways. Finally, megakaryocytic differentiation and platelet generation were determined using HPCs with R- spondin2 treatment. Results: We found that R-spondin2 generated by hematopoiesis-supporting stromal cells significantly enhances hematopoietic differentiation of hPSCs. Supply of R-spondin2 exogenously at the early stage of mesoderm differentiation elevates the generation of APLNR+ cells. Furthermore, early treatment of cells with R-spondin2 enables us to increase the output of hPSC-derived platelet-like particles (PLPs) with intact function. At the mechanistic level, R-spondin2 activates TGF-β signaling to promote the hematopoietic differentiation.
    [Show full text]